Cipla Gulf News Today

Ciplas Gulf arm to market, sell 4 biosimilar medicines in NZ, Australia Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand, the company said in a regulatory filing PTI | March 3, 2021 | Updated 07:47 IST Drug major Cipla on Tuesday said its Gulf subsidiary is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. C...

Cipla announced that its subsidiary, Cipla Gulf FZ LCC (Cipla Gulf) is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of the biologic medicine brands, Aflibercept (Eylea), Ustekimumab (Stelara), Denosumab (Prolia, Xgeva) and Golimumab (Simponi). These are leading products covering therapeutic cate...

Cipla Gulf expands partnership with Alvotech Premium 1 min read . Updated: 02 Mar 2021, 10:53 AM IST PTI Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand Share Via Read Full Story Drug major Cipla on Tuesday said its Gulf subsidiary is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. Cipla Gulf FZ LCC is e...

Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

Key equity indices advanced for the second session and closed near the days high with strong gains on Tuesday. The Nifty managed to close above the crucial 14,900 mark. Barring the Nifty PSU Bank index, all other sectoral indices on the NSE ended in the green. Positive development surrounding global COVID-19 vaccination programmes and stabilizing US Treasury yields boosted sentiment. Buying was also triggered as Indias GST collection for the month of February stood above the Rs 1 lakh crore ma...

Read more about Ciplas Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand on Business Standard. Cipla Gulf will be responsible for commercialisation of patented biosimilars of the biologic medicine brands -- Aflibercept, Ustekimumab,Denosumab and Golimumab.

Read more about Indices hit days high; Nifty above 14,900 mark on Business Standard. The barometer indices edged higher and hit the days high in morning trade. The Nifty reclaimed the 14,900 mark. All sectoral indices on the NSE were trading in the green. At 10:24 IST, the barometer index, the S&P BSE Sensex, was up 478.12 points

The drug major has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan nasal spray, 20 mg from the United States Food and Drug Administration (USFDA). The product is an AB-rated generic therapeutic equivalent version of GlaxoSmithKlines Imitrex nasal spray. Imitrex is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults. According to IQVIA (IMS Health), Imitrex nasal spray 20 mg and its ge...

Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf) is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible fo...

Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand Gulf FZ LCC ("Cipla Gulf), subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" and biopharmaceutical company Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of ...